{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-086806","form_type":"8-K","ticker":"INVA","cik":"0001080014","company_name":"Innoviva, Inc.","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.091629+00:00","generated_at":"2026-06-12T11:18:45.841878+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Innoviva Q2 2023: GSK royalties $65.7M, XACDURO FDA approved, net income $1.3M","bullets":["GSK royalties of $65.7M (RELVAR/BREO $54.4M, ANORO $11.3M) vs $111.7M in Q2 2022 due to TRELEGY royalty sale.","Net product sales $15.7M (GIAPREZA $11.2M, XERAVA $4.5M); $3.0M license milestone from XACDURO FDA approval.","Net income $1.3M ($0.02 basic EPS) vs $0.9M ($0.01) in Q2 2022; cash + receivables $254M.","Repurchased 775,504 shares for $9.2M in Q2 2023; invested $25M in Armata (NYSE: ARMP) on July 11, 2023.","On May 23, 2023, FDA approved XACDURO for HABP/VABP caused by Acinetobacter; launch expected H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-086806","json":"https://secwatch.observer/filing/0001104659-23-086806.json","markdown":"https://secwatch.observer/filing/0001104659-23-086806.md","text":"https://secwatch.observer/filing/0001104659-23-086806.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1080014/000110465923086806/0001104659-23-086806-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1080014/000110465923086806/tm2322589d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T11:18:45.841878+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"be22eae113da2a89e7dc9ba00cc8989ae6f53a24","claim":"Innoviva, Inc. reported the second quarter ended June 30, 2023 results: net income $1.3 million, or $0.02 basic per share, EPS $0.02 basic per share.","evidence_excerpt":"Innoviva, Inc. (the \"Company\") issued a press release regarding its results of operations and financial condition for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1080014/000110465923086806/0001104659-23-086806-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"$1.3 million, or $0.02 basic per share"},{"label":"EPS","value":"$0.02 basic per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}